<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05094050</url>
  </required_header>
  <id_info>
    <org_study_id>M20-339</org_study_id>
    <nct_id>NCT05094050</nct_id>
  </id_info>
  <brief_title>Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease</brief_title>
  <official_title>Parkinson's Disease: A Comparative Study of Levodopa and Carbidopa Bioavailability Following Foslevodopa/Foscarbidopa Infusion at Different Subcutaneous Sites in Parkinson's Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parkinson's disease (PD) is a neurological condition, which means it affects the brain. This&#xD;
      study will evaluate how ABBV-951 is absorbed under the skin of participants with PD when&#xD;
      administered to arm, thigh and flank compared to the abdomen.&#xD;
&#xD;
      ABBV-951 is an investigational drug being developed for the treatment of PD. Study doctors&#xD;
      randomly assign participants to 1 of 4 groups, called treatment arms. Each treatment arm&#xD;
      receives ABBV-951 administered in a different order in the arm, high, flank and abdomen.&#xD;
      Approximately 12 adult participants over 30 years with a diagnosis of PD will be enrolled in&#xD;
      approximately 10 sites in the United States.&#xD;
&#xD;
      Participants will receive continuous (24hours/day) subcutaneous infusion of ABBV-951 for 2&#xD;
      consecutive days for each infusion site (arm, thigh, flank and abdomen), for a total duration&#xD;
      of treatment up to 12 days.&#xD;
&#xD;
      There may be higher treatment burden for participants in this trial compared to their&#xD;
      standard of care. Participants will be confined at a hospital or clinic. The effect of the&#xD;
      treatment will be checked by medical assessments, blood tests, checking for side effects and&#xD;
      completing questionnaires. Adverse events will be monitored throughout the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 21, 2021</start_date>
  <completion_date type="Anticipated">October 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 17, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Levodopa (LD)</measure>
    <time_frame>Up to 8 Days</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of Levodopa (LD).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve (AUC) for the 24-hour Interval of LD</measure>
    <time_frame>Up to 8 Days</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) for the 24-hour interval of LD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum Observed Plasma Concentration (Cmin) of LD</measure>
    <time_frame>Up to 8 Days</time_frame>
    <description>Minimum observed plasma concentration (Cmin) of LD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Degree of Fluctuation (DFL) of LD</measure>
    <time_frame>Up to 8 Days</time_frame>
    <description>DFL = (Cmax-Cmin)/(average plasma concentration).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Swing of LD</measure>
    <time_frame>Up to 8 Days</time_frame>
    <description>Swing = (Cmax-Cmin)/Cmin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Carbidopa (CD)</measure>
    <time_frame>Up to 8 Days</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of CD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve (AUC) for the 24-hour Interval of CD</measure>
    <time_frame>Up to 8 Days</time_frame>
    <description>Area under the plasma concentration-time curve (AUC) for the 24-hour interval of CD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum Observed Plasma Concentration (Cmin) of CD</measure>
    <time_frame>Up to 8 Days</time_frame>
    <description>Minimum observed plasma concentration (Cmin) of CD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Degree of Fluctuation (DFL) of CD</measure>
    <time_frame>Up to 8 Days</time_frame>
    <description>DFL = (Cmax-Cmin)/(average plasma concentration).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Swing of CD</measure>
    <time_frame>Up to 8 Days</time_frame>
    <description>Swing = (Cmax-Cmin)/Cmin.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Arm 1: ABBV-951</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ABBV-951 for 2 consecutive days in the abdomen (Period 1), flank (Period 2), arm (Period 3) and thigh (Period 4).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: ABBV-951</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ABBV-951 for 2 consecutive days in the arm (Period 1), abdomen (Period 2), thigh (Period 3) and flank (Period 4).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: ABBV-951</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ABBV-951 for 2 consecutive days in the thigh (Period 1), arm (Period 2), flank (Period 3) and abdomen (Period 4).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: ABBV-951</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ABBV-951 for 2 consecutive days in the flank (Period 1), thigh (Period 2), abdomen (Period 3) and arm (Period 4).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-951</intervention_name>
    <description>Continuous Subcutaneous Infusion (CSCI)</description>
    <arm_group_label>Arm 1: ABBV-951</arm_group_label>
    <arm_group_label>Arm 2: ABBV-951</arm_group_label>
    <arm_group_label>Arm 3: ABBV-951</arm_group_label>
    <arm_group_label>Arm 4: ABBV-951</arm_group_label>
    <other_name>Foslevodopa/foscarbidopa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of idiopathic Parkinson's disease (PD) that is Levodopa-responsive.&#xD;
&#xD;
          -  Must be taking a minimum of 400 mg/day of levodopa equivalents (LE) and be judged by&#xD;
             the investigator to have motor symptoms inadequately controlled by current therapy.&#xD;
&#xD;
          -  Must have recognizable/identifiable &quot;Off&quot; and &quot;On&quot; states (motor fluctuations), and&#xD;
             have a minimum daily average of 2.5 hours of &quot;Off&quot; time (with a minimum of 2 hours of&#xD;
             &quot;Off&quot; time each day).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - History of significant skin conditions or disorders (e.g., psoriasis, atopic dermatitis,&#xD;
        etc.) or evidence of recent sunburn, acne, scar tissue, tattoo, open wound, branding, or&#xD;
        colorations that in the investigator's opinion would interfere with the infusion of the&#xD;
        study drug or could interfere with study assessments.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado Hosp /ID# 229974</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital /ID# 230224</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M3 Wake Research Inc. /ID# 239836</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612-8106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Movement Disorder Clinic of Oklahoma /ID# 238610</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136-6378</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center /ID# 230255</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-0011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Movement Disorder Specialist /ID# 238607</name>
      <address>
        <city>Georgetown</city>
        <state>Texas</state>
        <zip>78628-4126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Foslevodopa/foscarbidopa</keyword>
  <keyword>ABBV-951</keyword>
  <keyword>Levodopa (LD)</keyword>
  <keyword>Carbidopa (CD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

